The Precharting System That Actually Saves Time
This transcript has been edited for clarity.
Let's talk about precharting — that early morning scramble to review your patients before rounds. To do it efficiently, you need a system.
Start with your own list of patients and tackle them one by one. Try not to bounce around. First, scan vitals, overnight events, and new labs. Look for trends, not just numbers;for example, whether a fever is resolving or a creatinine is up-trending.
Next, check notes from the night team or nursing updates for any changes or issues that came up. Then, review medications, especially any new ones started overnight.
Finally, take a moment to mentally prepare your assessment and plan.It's nice to have a rough idea of what you're going to say on rounds.
The goal of precharting is focused, high-yield review: enough to know what happened, what's going on now, and what you're going to recommend. That is efficient precharting.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Podiatry Practice moves to new location in Salisbury
A podiatry practice has moved to a new location. Sarum Podiatry Practice has relocated from Milford Street to Castle Street, Salisbury. The practice, run by Susan Dawkins, BSc (Hons) MRCOP, HCPC Registered Podiatrist, is now at 56 Castle Street. Ms Dawkins said: "We look forward to seeing you at our new premises." The new location is described as "spacious" and "newly renovated." While the front of the practice is still being refurbished, it is open for business. Contact details remain the same: 01722 500408 or sarumpodiatry@
Yahoo
35 minutes ago
- Yahoo
Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors
Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the appointment of Dr. Joon Sup Lee as an independent director to its Board of Directors. The appointment went into effect on June 18, 2025. A healthcare specialist in the laboratory testing an Oncology-related product. Dr. Lee's appointment was a result of Medtronic increasing the size of its Board. The new director will serve on the Board's Science and Technology Committee and the Compensation and Talent Committee. Dr. Lee is currently the CEO of Emory Healthcare, Inc., overseeing Georgia's most comprehensive academic health system. Before joining Emory Healthcare, Dr. Lee was the executive director of the University of Pittsburgh Medical Center's (UPMC) Heart and Vascular Institute from 2018 to 2020. He was also a professor of medicine at the University of Pittsburgh School of Medicine. He held various leadership roles at UPMC, including Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory. Medtronic plc (NYSE:MDT) is an Irish-domiciled healthcare technology company. It develops and sells medical devices and therapies for chronic conditions across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its top products include heart devices, spinal implants, surgical tools, insulin pumps, and neuromodulation systems. Medtronic serves over 79 million patients annually in more than 150 countries. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the shares of Regulus ceased trading on the NASDAQ exchange, and the company became a fully owned subsidiary of Novartis. lucarista/ The acquisition marks a crucial step in the company's effort to advance the clinical development of a potential first-in-class medicine for autosomal dominant polycystic kidney disease. Regulus Joins Novartis with Farabursen, an investigational next-generation oligonucleotide aiming to reduce the growth of cysts and kidney size. Novartis is a global healthcare company dedicated to discovering and developing innovative medicines that improve and extend people's lives. It also focuses on addressing significant medical challenges, including cancer and rare genetic disorders, by prioritizing research and development, as well as innovative access approaches. Novartis AG (NYSE:NVS) is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines to improve and extend people's lives. It also focuses on using science-based innovation to address significant healthcare challenges. Novartis operates in over 100 countries, with the US accounting for about one-third of its revenue. While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
